IgG subclass switching and clonal expansion in cutaneous melanoma and normal skin

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Saul, Louise ^a,b   Ilieva, Kristina M ^a,b   Bax, Heather J ^a,b   Karagiannis, Panagiotis ^a   Correa, Isabel ^a   Rodriguez Hernandez, Irene ^c   Josephs, Debra H ^a,b   Tosi, Isabella ^a   Egbuniwe, Isioma U ^a   Lombardi, Sara ^a,d   Crescioli, Silvia ^a   Hobbs, Carl ^e   Villanova, Federica ^a   Cheung, Anthony ^a,b   Geh, Jenny L C ^a   Healy, Ciaran ^a   Harries, Mark ^f   Sanz Moreno, Victoria ^c   Fear, David J ^b   Spicer, James F ^b   Lacy, Katie E ^a,d   Nestle, Frank O ^a   Karagiannis, Sophia N ^a   more..

^a ST THOMAS HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CD22 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

B LYMPHOCYTE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOLOGY; MELANOMA; METABOLISM; PROCEDURES; SKIN; SKIN TUMOR;

B-LYMPHOCYTES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; MELANOMA; SIALIC ACID BINDING IG-LIKE LECTIN 2; SKIN; SKIN NEOPLASMS;

EID: 84978732966     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep29736     Document Type: Article

References (51)

1. Wabl, M. & Steinberg, C. Afnity maturation and class switching. Curr Opin Immunol. 8, 89-92 (1996).
2. Edry, E., Koralov, S. B., Rajewsky, K. & Melamed, D. Spontaneous class switch recombination in B cell lymphopoiesis generates aberrant switch junctions and is increased afer VDJ rearrangement. J Immunol. 179, 6555-6560 (2007).
3. Gould, H. J., Takhar, P. , Harries, H. E., Durham, S. R. & Corrigan, C. J. Germinal-centre reactions in allergic infammation. Trends Immunol. 27, 446-452, doi: 10.1016/j.it.2006.08.007 (2006).
4. Geherin, S. A. et al. The skin, a novel niche for recirculating B cells. J Immunol. 188, 6027-6035, doi: 10.4049/jimmunol.1102639 (2012).
5. Lafyatis, R. et al. B cell depletion with rituximab in patients with difuse cutaneous systemic sclerosis. Arthritis Rheum. 60, 578-583, doi: 10.1002/art.24249 (2009).
6. Simon, D., Hösli, S., Kostylina, G., Yawalkar, N. & Simon, H. U. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 121, 122-128, doi: 10.1016/j.jaci.2007.11.016 (2008).
7. de Visser, K. E., Korets, L. V. & Coussens, L. M. De novo carcinogenesis promoted by chronic infammation is B lymphocyte dependent. Cancer Cell 7, 411-423, doi: 10.1016/j.ccr.2005.04.014 (2005).
8. Karagiannis, P. et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest. 123, 1457-1474, doi: 10.1172/ JCI65579 (2013).
9. Cipponi, A. et al. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72, 3997-4007, doi: 10.1158/0008-5472.CAN-12-1377 (2012).
10. Mizukami, M. et al. Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth. Anticancer Res. 26, 1827-1831 (2006).
11. Kabbarah, O. et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One 5, e10770, doi: 10.1371/journal. pone.0010770 (2010).
12. Riker, A. I. et al. The gene expression profles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1, 13, doi: 10.1186/1755-8794-1-13 (2008).
13. Xu, L. et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 6, 760-769, doi: 10.1158/1541-7786.MCR-07-0344 (2008).
14. Ladányi, A. et al. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 60, 1729-1738, doi: 10.1007/s00262-011-1071-x (2011).
15. Erdag, G. et al. Immunotype and immunohistologic characteristics of tumor-infltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 72, 1070-1080, doi: 10.1158/0008-5472.CAN-11-3218 (2012).
16. Ladányi, A. Prognostic and predictive signifcance of immune cells infltrating cutaneous melanoma. Pigment Cell Melanoma Res. 28, 490-500, doi: 10.1111/pcmr.12371 (2015).
17. French, M. Serum IgG subclasses in normal adults. Monographs in Allergy 19, 100-107 (1986).
18. Papadea, C. & Check, I. J. Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects. Critical Reviews in Clinical Laboratory Sciences 27, 27-58 (1989).
19. Xu, J. L. & Davis, M. M. Diversity in the CDR3 region of V(H) is sufcient for most antibody specifcities. Immunity 13, 37-45 (2000).
20. Miqueu, P. et al. Statistical analysis of CDR3 length distributions for the assessment of T and B cell repertoire biases. Mol Immunol. 44, 1057-1064, doi: 10.1016/j.molimm.2006.06.026 (2007).
21. Caton, A. J., Swartzentruber, J. R., Kuhl, A. L., Carding, S. R. & Stark, S. E. Activation and negative selection of functionally distinct subsets of antibody-secreting cells by infuenza hemagglutinin as a viral and a neo-self antigen. J Exp Med. 183, 13-26 (1996).
22. Yaari, G., Uduman, M. & Kleinstein, S. H. Quantifying selection in high-throughput Immunoglobulin sequencing data sets. Nucleic Acids Res. 40, e134, doi: 10.1093/nar/gks457 (2012).
23. Coker, H. A. et al. Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol. 116, 445-452, doi: 10.1016/j.jaci.2005.04.032 (2005).
24. Yang, J. & Zhang, Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 43, W174-W181, doi: 10.1093/nar/gkv342 (2015).
25. Hussein, M. R. Tumour-associated macrophages and melanoma tumourigenesis: integrating the complexity. Int J Exp Pathol. 87, 163-176, doi: 10.1111/j.1365-2613.2006.00478.x (2006).
26. Yeilding, N. M., Gerstner, C. & Kirkwood, J. M. Analysis of two human monoclonal antibodies against melanoma. Int J Cancer 52, 967-973 (1992).
27. Yamaguchi, H. et al. Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci USA 84, 2416-2420 (1987).
28. Kantele, A. et al. Cutaneous lymphocyte antigen expression on human efector B cells depends on the site and on the nature of antigen encounter. European Journal of Immunology 33, 3275-3283 (2003).
29. Ganti, S. N., Albershardt, T. C., Iritani, B. M. & Ruddell, A. Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth. Sci Rep. 5, 12255, doi: 10.1038/srep12255 (2015).
30. Aalberse, R. The role of IgG antibodies in allergy and immunotherapy. Allergy 66 Suppl 95, 28-30, doi: 10.1111/j.1398-9995.2011.02628.x (2011).
31. van de Veen, W. et al. IgG4 production is confned to human IL-10-producing regulatory B cells that suppress antigen-specifc immune responses. J Allergy Clin Immunol. 131, 1204-1212, doi: 10.1016/j.jaci.2013.01.014 (2013).
32. Crescioli, S. et al. IgG4 Characteristics and Functions in Cancer Immunity. Curr Allergy Asthma Rep. 16, 7, doi: 10.1007/s11882-015-0580-7 (2016).
33. Karagiannis, P. et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. OncoImmunology 4, e1032492, doi: 10.1080/2162402X.2015.1032492 (2015).
34. Nagel, A. et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specifc IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 129, 2202-2210, doi: 10.1038/jid.2009.27 (2009).
35. Siber, G. R. et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med. 323, 1387-1392, doi: 10.1056/NEJM199011153232005 (1990).
36. von Gunten, S. et al. Intravenous immunoglobulin contains a broad repertoire of anticarbohydrate antibodies that is not restricted to the IgG2 subclass. J Allergy Clin Immunol. 123, 1268-1276, e1215, doi: 10.1016/j.jaci.2009.03.013 (2009).
37. Carlsen, T. G. et al. IgG subclass antibodies to human and bacterial HSP60 are not associated with disease activity and progression over time in axial spondyloarthritis. Arthritis Res Ter. 15, R61, doi: 10.1186/ar4234 (2013).
38. Hjelholt, A., Christiansen, G., Sørensen, U. S. & Birkelund, S. IgG subclass profles in normal human sera of antibodies specifc to fve kinds of microbial antigens. Pathog Dis. 67, 206-213, doi: 10.1111/2049-632X.12034 (2013).
39. Giuntini, S., Reason, D. C. & Granof, D. M. Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein. Infect Immun. 80, 187-194, doi: 10.1128/IAI.05956-11 (2012).
40. Greenspan, N. S. et al. IgG3 defciency extends lifespan and attenuates progression of glomerulonephritis in MRL/lpr mice. Biol Direct. 7, 3, doi: 10.1186/1745-6150-7-3 (2012).
41. Batista, F. D. & Neuberger, M. S. Afnity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of of-rate. Immunity 8, 751-759 (1998).
42. Chimen, M. et al. Homeostatic regulation of T cell trafcking by a B cell-derived peptide is impaired in autoimmune and chronic infammatory disease. Nat Med. 21, 467-475, doi: 10.1038/nm.3842 (2015).
43. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306-313, doi: 10.1038/nature10762 (2012).
44. Gubin, M. M. et al. Checkpoint blockade cancer immunotherapy targets tumour-specifc mutant antigens. Nature 515, 577-581, doi: 10.1038/nature13988 (2014).
45. van Zelm, M. C. B cells take their time: sequential IgG class switching over the course of an immune response? Immunol Cell Biol. 92, 645-646, doi: 10.1038/icb.2014.48 (2014).
46. Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classifcation. J Clin Oncol. 27, 6199-6206, doi: 10.1200/ JCO.2009.23.4799 (2009).
47. Brochet, X., Lefranc, M. P. & Giudicelli, V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 36, W503-W508, doi: 10.1093/nar/gkn316 (2008).
48. Altschul, S. F. , Gish, W. , Miller, W. , Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J Mol Biol. 215, 403-410, doi: 10.1016/S0022-2836(05)80360-2 (1990).
49. Vidarsson, G., Dekkers, G. & Rispens, T. IgG subclasses and allotypes: from structure to efector functions. Front Immunol. 5, 520, doi: 10.3389/fmmu.2014.00520 (2014).
50. Reich, M. et al. GenePattern 2.0. Nat Genet. 38, 500-501, doi: 10.1038/ng0506-500 (2006).
51. Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profles using the cBioPortal. Sci Signal 6, pl1, doi: 10.1126/ scisignal.2004088 (2013).